In conclusion, the results of this study showed that the recurrence of CIP in a real-world lung cancer patients' cohort receiving ICIs-therapies is not an uncommon event. Recurrence of CIP was more frequently reported in males, squamous histology or patients who received chest radiotherapy. Squamous NSCLC patients and a duration of prednisolone equivalent dose ≥15 mg/day more than 4 weeks have been associated with an decreased risk of CIP recurrence. Based on these findings a duration of prednisolone equivalent dose ≥15 mg/day of at least 4 weeks during the tapering process of corticosteroids may be warranted. Further studies including larger cohorts of patients are needed to verify this preliminary observation.
The authors appreciate the academic support from the AME Lung Cancer Collaborative Group.
This study was supported by the Major Research plan of the National Health Commission (No. GWJJ2021100304).
The authors have completed the STROBE reporting checklist. Available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-22-168/rc
Data Sharing Statement
Available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-22-168/dss
The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). The study was approved by ethics board of Chinese PLA General Hospital (No. S2021-562-01). Individual consent for this retrospective analysis was waived.
Transl Lung Cancer Res. 2022;11(3):381-392. © 2022 AME Publishing Company